A French bioelectronics company “Pixium Vision SA” (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), based in Paris, has announced the completion of implantations of an… Read More »Pixium SA has announced the completion of implantations of the “PRIMAvera” trial with the implantation of a bionic artificial retina.
Researchers at the UCL Institute of Ophthalmology, London and Moorfields Eye Hospital NHS Foundation Trust has reported a novel history of RP2 mutations arising from… Read More »A natural history of XLRP from RP2 mutations aim to facilitate trial endpoints for future clinical studies.
A systematic review on the epidemiology of RPE65 mutations reported in the literature showed that there were significant variations of RPE65 proportions within countries as… Read More »A systematic literature review on the epidemiology of RPE65 mutations report significant variations in the literature within countries as well as regions.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 8th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »January 8th, 2023 “EURETINA-Brief”© Issue No. 264
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the FDA clearance of its Investigational New Drug (IND)… Read More »Opus Genetics Inc., has announced an IND application for “OPGx-001” for the treatment of LCA5 retinal disease
An interim analysis from a Phase II study for a novel peptide (THR-149) is aimed to prevent the induction of retinal vascular permeability, neurodegeneration and… Read More »Phase II data on a novel peptide candidate – plasma kallikrein (PKal) (THR-149) – for treatment of diabetic macular edema (DME)
Researchers at the Birmingham and Midland Eye Centre, UK, has reported five-years’ of real-world results from the application of the fluocinolone acetonide implant (ILUVIEN), for… Read More »Five-year real-world results on intravitreal fluocinolone treatment of chronic diabetic macular oedema (DMO) has shown improved or stabilised VA
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 17th, 2022 edition of EURETINA’s web-based… Read More »December 17th, 2022 “EURETINA-Brief”© Issue No. 263
IVERIC bio, Inc., (NASDAQ: ISEE), based in Parsippany New Jersey, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for… Read More »Avacincaptad pegol (ACP, “Zimura”) for geographic atrophy (IVERIC bio, Inc., NASDAQ: ISEE)) has announced a Breakthrough Therapy Designation from the FDA
Despite positive initial clinical data from an ongoing open label Phase I/II “BRILLIANCE” study, named EDIT-101, a CRISPR-based experimental treatment for the treatment of Leber… Read More »Pausing of CRISPR gene editing therapy for LCA CEP290-related retinal degeneration from >15 patients